Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
COR · NYSE · Healthcare
Fundamental quality
57
out of 100
Cencora, Inc. earns a fundamental-quality score of 57 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its growth (revenue +10.5%/yr). Its weakest area is its financial strength (net debt 2.68× EBITDA). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Cencora (formerly AmerisourceBergen) is another of the three giants of US pharmaceutical distribution, especially strong in specialty drugs: oncology and expensive, delicate therapies demanding precision logistics. Walgreens was for years its partner and anchor shareholder.
EPS growth: 13.5% · Revenue growth: 10.5%
Net margin: 0.8% · ROE: 75% · ROIC: 14.9%
Net debt/EBITDA: 2.68x · FCF: 0.5%
Source: SEC EDGAR · TTM through 31/03/2026
The score includes +4 for dividend strength: 17 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its financial strength drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 189,894 | -3,409 | 1,837 | -580 |
| 2021 | 213,989 | 1,540 | 2,228 | 3,837 |
| 2022 | 238,587 | 1,699 | 2,207 | 2,315 |
| 2023 | 262,173 | 1,745 | 3,453 | 2,195 |
| 2024 | 293,959 | 1,509 | 2,998 | 1,255 |
| 2025 | 321,333 | 1,554 | 3,207 | 3,305 |
Between 2020 and 2025, revenue went from $189,894M to $321,333M (+69%) and net income went from -$3,409M to $1,554M (+146%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended March 31, 2026, versus the half-year ended March 31, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$2.2
per share, yearly
28.1% of earnings
Payout
at least 17 straight years raising it
Growth
That is what we can verify in the SEC filings, whose structured data only starts in 2008 and which many companies begin tagging later. The real streak may be considerably longer.
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Cencora, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Cencora, Inc. a good company to invest in?
In terms of business quality, Cencora, Inc. scores 57 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Cencora, Inc. a profitable company?
Cencora, Inc. is profitable, with a net margin of 0.8%, though a thin one.
Does Cencora, Inc. have a lot of debt?
A moderate level: its net debt is 2.68 times its EBITDA.
Is Cencora, Inc. growing?
Its revenue has grown 10.5% annualized in recent years and its earnings per share 13.5%, and without interruption since 2020.
Does Cencora, Inc. generate cash?
Yes. It converts about 0.5% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Insulet (PODD) · Edwards Lifesciences (EW) · Molina Healthcare (MOH) · Medline (MDLN) · Tenet Healthcare (THC) · Universal Health Services (UHS) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Cencora, Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.